Solstice Q3 2026: Progress on Electronics, Margin Pressure Persists

What happened

Solstice Advanced Materials reported Q3 2026 results that showed continued revenue growth but gross margin remained stuck near 32%, failing to break above the 33% threshold needed to validate the investment thesis. Electronics materials sales grew again in the quarter, but the growth was not enough to offset higher raw material costs and the drag from the refrigerants segment. Management reaffirmed the 2026 adjusted EBITDA guidance range but acknowledged that deleveraging would be slower than initially expected, with net leverage likely to stay above 3x for longer than 18 months. The pending Element Solutions acquisition remains on track to close by early 2027, but the integration plan now assumes lower near-term synergies due to softer end-market demand. Overall, the earnings call confirmed that Solstice is executing on its strategic priorities but has yet to demonstrate the margin improvement that would justify a higher valuation.

Implication

Investors should maintain a cautious stance as Solstice's gross margin has not improved meaningfully since the spin, and the company's valuation already reflects optimistic assumptions about electronics growth and synergy capture. The failure to show margin expansion in Q3 suggests that the company may not achieve its 2026 EBITDA guidance without further cost actions, which could pressure earnings. The slower deleveraging path increases balance-sheet risk, especially if the Element acquisition closes with higher-than-expected leverage. Upside potential appears limited unless the company can demonstrate sustainable margin improvement above 33% or the market re-rates the stock based on clearer evidence of earnings power. We would consider upgrading if future quarters show gross margin above 33% and electronics growth accelerates, but until then, the risk-reward remains unattractive.

Thesis delta

The Q3 report did not materially change our thesis. The core issue remains the lack of margin improvement, and the company's guidance suggests that deleveraging will take longer than previously expected. We maintain our WAIT rating and $52 attractive entry, with no change to the $61 base-case value.